Tanya Dorff, M.D.
Tanya Barauskas Dorff, M.D., is an associate clinical professor in the Department of Medical Oncology & Therapeutics Research and serves as head of the genitourinary cancers program at City of Hope. She is an internationally recognized leader in prostate cancer
, and is renowned for her work in other genitourinary tumor types, including kidney
and penile cancer.
Dr. Dorff graduated summa cum laude from the University of Houston before attending the UCLA School of Medicine. There, she was inducted into the prestigious Alpha Omega Alpha honors society. She subsequently completed her internal medicine residency at Mt. Sinai Hospital in New York, and finished subspecialty training in hematology and oncology at Los Angeles County + USC Medical Center.
Dr. Dorff remained on the faculty at USC after completing her training, eventually amassing over 70 publications in top-tier journals, including Cancer
, Lancet Oncology
and Journal of Clinical Oncology
. She has been invited to speak at multiple national and international meetings, and serves on the American Society of Clinical Oncology Scientific Committee and the National Cancer Institute Prostate Cancer Task Force.
Dr. Dorff’s research interests in prostate cancer are wide ranging. In the area of clinical trials, she has been heavily involved in the design and conduct of trials related to PSA-recurrent prostate cancer, referring to the setting in which local therapies (e.g., surgery and radiation) fail and blood-based markers (namely PSA) continue to rise. For patients with more advanced prostate cancer, she has studied the role of fasting as it pertains to chemotherapy tolerability, with very compelling early results.
Dr. Dorff leads City of Hope’s joint effort with the Prostate Cancer Foundation to develop novel immune-based strategies for prostate cancer. Specifically, she leads an effort to develop chimeric antigen receptor (CAR) T cells – cells that are primed to target prostate cancer tissue. These strategies have been transformative in certain blood-based cancers. She will also be engaging with laboratory scientists Jeremy Jones, Ph.D., and Marcin Kortylewski, Ph.D., who are developing first-in-human agents to combat prostate cancer through other novel mechanisms.
Dr. Dorff has assumed control of one of the largest clinical trial portfolios in genitourinary cancers, and will be seeing patients with prostate
and penile cancer.